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Exosomes are nanometer-sized vesicles (40–100 nm diameter) of endocytic origin released
from different cell types under both normal and pathological conditions. They function as cell
free messengers, playing a relevant role in the cell–cell communication that is strongly related
to the nature of the molecules (proteins, mRNAs, miRNAs, and lipids) that they transport.
Tumor cells actively shed exosomes into their surrounding microenvironment and growing
evidence indicates that these vesicles have pleiotropic functions in the regulation of tumor
progression, promoting immune escape, tumor invasion, neovascularization, and metastasis.
During the last few years remarkable efforts have been made to obtain an accurate definition
of the protein content of tumor-derived exosomes (TDEs) by applying MS-based proteomic
technologies. To date, TDEs proteomic studies have been mainly utilized to catalog TDEs
proteinswith the purpose of identifying disease biomarkers. The future challenge for improving
our understanding and characterization of TDEs will be the implementation of new systems-
driven and proteomic integrative strategies. The aim of this article is to provide an overview of
the most characterized exosomes-mediated mechanisms that contribute to the pathogenesis of
cancer and to review recent proteomics data that support the protumorigenic role of TDEs.
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1 Introduction
Cell-to-cell communication in a living multicellular organ-
ism is an essential process that promotes and coordinates the
activities among different groups of cells, creating a coopera-
tive whole. Classically, cells are thought to communicate with
each other via direct contact (juxtacrine signaling) or via sol-
uble mediators (autocrine, paracrine, and endocrine signal-
ing). However, during the last few years an understanding of
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the function of membrane-limited vesicles released by cells
in transferring small packages of information to target cells
is rapidly emerging. Among them, exosomes seem to play a
relevant role in trans signaling to neighboring cells.
Exosomes are nanometer-sized vesicles that represent a
distinct class of membrane vesicles (40–100 nm diameter) of
endocytic origin that are released from different cell types un-
der both normal and pathological conditions [1,2]. In addition
to cultured cells, exosomes have further been isolated from a
number of body fluids such as plasma [3], urine [4], synovial
fluid [5], malignant effusions [6], epididymal fluid [7], and
from seminal plasma [8].
Exosomes are derived from the intraluminal vesicles
(ILVs) of multivesicular bodies (MVBs), formed through the
reversed budding of the limiting membrane of late endo-
somes. During biogenesis, ILVs encapsulate material from
cytoplasm including RNA (both mRNA and microRNA) and
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Figure 1. Mechanisms of intercellular communication mediated by exosomes. (A) Exosomes can bind to cells through receptor-ligand
interactions and activate intracellular signaling. (B) Exosomes can fuse with the target cell membrane and deliver exosomal membrane
and cytoplasm proteins to the recipient cell. The plasma membrane of the target cells can be also modified by the addition of new
membrane receptors and different lipid components. Exosomal molecules (proteins, mRNAs, and miRNAs) can activate a multitude of
signaling events in the recipient target cell. (C) An alternative exosome–cell interaction mechanism is represented by phagocytosis.
proteins [9,10].Multivesicular bodies can fusewith lysosomes
to degrade their content or with the plasma membrane to re-
lease the ILVs into the extracellular space. These vesicles,
referred to as exosomes, display the endocytosed transmem-
brane proteins in the same orientation as those in the plasma
membrane [11]. According to their origin, exosomes contain
endocytic markers, i.e. tetraspanins and HSPs (as Hsc70 and
Hsp90).
Initially, exosomes were described as vesicles released by
reticulocytes, and they were thought to function as a way
to remove unnecessary proteins, such as the transferrin re-
ceptor, during the maturation process into erythrocytes [12].
However, emerging evidence indicates exosomes as cell free
messengers that play, within a tissue microenvironment, a
relevant role in cell–cell communication [13]. Thus, today
they are seen as novel mediators of intercellular signaling
that act independently but synergistically with soluble growth
factors [14]. How exosomes may interact with a target cell
is not yet fully known and several mechanisms have been
hypothesized (Fig. 1) [15–17]. As shown in Fig. 1A, exoso-
mal membrane proteins can interact with the target cell in
a juxtacrine fashion, acting as ligands for receptors on the
cell surface. Additionally, exosomes can also fuse with the
target cell resulting in the nonselective transfer of proteins
and RNA from the exosome to the target cell (Fig. 1B). Fi-
nally, in a recent paper Feng et al. showed that in phagocytic
cells, exosomes can be internalized efficiently via phagocy-
tosis [15]. Their data demonstrated that exosomes promptly
adhered to the cell surface of nonphagocytic cells but were
not internalized, as they could be experimentally removed
by trypsinization or with extensive acid washing. In con-
trast, the same treatment did not remove exosomes from
phagocytes [15].
As result of each of these interaction mechanisms, exo-
somes are able to modulate selected cellular activities and
participate in the signaling events regulating both physiolog-
ical and pathological processes [2].
In the last decade, a large number of studies have shown
that tumor cells constitutively release exosomes [18]. Their de-
tection in supernatants of cancer cells in culture as well as in
plasma, sera, and other bodyfluids of cancer patients has been
widely reported [19–21] and all available data strongly support
the protumorigenic role of tumor-derived exosomes (TDEs).
Currently, MS-based proteomic technologies represent one
of most powerful tools for an in-depth characterization of
TDEs, providing a global view of their protein content. The
present review is focused on two related aspects: (i) to pro-
vide an overview of themost characterized exosome-mediated
mechanisms contributing to the pathogenesis of cancer
(Fig. 2); (ii) to review recent proteomic data that support the
protumorigenic role of TDEs.
2 Role of TDEs in shaping the tumor
microenvironment
Cancer cells begin to mold their stromal environment start-
ing with the early phases of the neoplastic process. Today, it is
known that in addition to pathways involving cell-to-cell con-
tact and the release of soluble factors, such as TNF, TGF,
VEGF, cancer cells are able to communicate with other cells
of a tumor microenvironment (e.g. myeloid cells, fibroblasts)
through the intercellular exchange of proteins and genetic
materials via exosomes [22].
One of the first interesting clues concerning the under-
standing of TDEs’ involvement in cancer was the presence
of antigen-presenting complexes, such as MHC class I and
II, and tumor antigens such as MelanA/Mart-1 and GP100,
the carcinoembryogenic antigen (CEA), and the human
epidermal growth factor receptor-2 (HER2) [23–26]. These
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Figure 2. Pleiotropic mechanisms supporting the protumorigenic role of TDEs. TDEsmodulate neoplastic cell growth via autocrine stimula-
tion and are also able to alter the premetastatic niche by promoting angiogenesis, extracellularmatrix degradation, and stromal remodeling.
They also create an immunosuppressive microenvironment by impairing the cytotoxic function of NK and CD8+ cells (1 and 2), by inducing
the apoptosis of T cells through FAS-FASL ligation (3) and by altering the monocyte differentiation into dendritic cells and leading to the
generation of myeloid suppressive cells (4). Furthermore, TDEs interfere with the action of therapeutic agents inducing drug resistance
and are implicated in transferring miRNAs and mRNAs to neighboring cells inducing gene expression modifications.
observations have led to the hypothesis that TDEs could have
an immunogenic ability to induce an effective antitumor im-
mune response, suggesting the use of exosomes as a new
delivery system for tumor antigens in cancer immunother-
apy [27]. However, despite these features, immunostimula-
tory and antitumor effects of TDEs are rarely observed in
tumors. Instead, most of the experimental data support the
hypothesis that TDEs play a role in preventing antitumor im-
mune responses and promoting tumorigenesis [28,29]. These
effects are essentially due to the ability of TDEs (i) to induce
a positive effect on neoplastic cell growth and survival, (ii) to
contribute to the establishment of a premetastatic niche by
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promoting angiogenesis, extracellular matrix (ECM) degra-
dation, and stromal remodeling, (iii) to have immunosup-
pressive effects, (iv) to interfere with the action of therapeutic
agents by inducing drug resistance [28–32]. TDEs are also in-
volved in transferring microRNAs (miRNAs) and mRNAs to
neighboring cells, thereby inducing gene expressionmodula-
tion [10, 33]. A schematic representation of these pleiotropic
mechanisms that support the protumorigenic effects of TDEs
is reported in Fig. 2.
2.1 TDEs induce tumor cells growth and survival
Several studies have reported that TDEs play a critical role
in the autocrine stimulation of cancer cells adding their ef-
fects to the protumoral action of soluble factors (Fig. 2). One
of the first evidence supporting this role showed that the
intercellular transfer of the oncogenic receptor EGFRvIII,
mediated by tumor exosomes to glioma cells lacking this
receptor, contributed to their morphological transformation
and anchorage-independent growth [34]. Furthermore, TDEs
transport apoptosis inhibitory proteins, such as survivin, a
member of the apoptosis inhibitor protein family [35], they
also present TGF- on their surface in association with be-
taglycan. Exosomal delivery of TGF- is capable of driving
the differentiation of fibroblasts into myofibroblasts, whose
enrichment in solid tumors provides an altered stroma that
supports tumor growth, vascularization, and metastasis [36].
2.2 Effects of TDEs in promoting the premetastatic
niche
Metastasis formation is a complex process that depends on
the ability of tumor cells to induce extensive modifications
in their microenvironment including (i) the degradation and
remodeling of the ECM; (ii) the formation of new blood ves-
sels (Fig. 2). TDEs are able to actively participate in shap-
ing a premetastatic niche since they transport several bio-
logically active molecules that play relevant roles in these
processes. ECM metalloproteinase inducers, matrix metallo-
proteinases (MMPs), VEGF, and integrins have been found
in exosomes [37–39]. Giusti et al. have also demonstrated
that exosomes, derived from cells established from the as-
citic fluid of a patient with ovarian cancer, show Cathepsin
B, a cystein protease, in their membrane which has a dual
effect on the ECM remodeling [40]. Other exosomal proteins
that have a positive effect on the invasive behavior of can-
cer cells are tetraspanins, cell-surface proteins spanning four
times the plasmamembrane [41]. They form both homocom-
plexes and heterocomplexes by interacting with a large variety
of transmembrane and cytosolic proteins [42]. Tetraspanins
promote cell spreading, cell migration, and cable formation
by regulating integrin compartmentalization, internalization,
recycling, and signaling [43,44]. In addition to enhancing the
invasiveness of cancer cells, TDEs contribute to the establish-
ment of ametastatic niche via the delivery of proteins,mRNAs
and miRNAs that support angiogenesis. Tetraspanins them-
selves have been found to contribute to exosome-mediated
angiogenesis by stimulating matrix metalloproteinase secre-
tion and VEGF expression [45] in target cells. TDEs also con-
tain several cytokines and growth factors, such as the tumor
necrosis factors TNF-, IL-1, and TGF- as well as func-
tional receptors such as TNFR1 that enhance the recruitment
of endothelial precursor cells thus promoting neoangiogene-
sis [46]. Hood et al. showed that melanoma-derived exosomes
stimulated endothelial cells by paracrine signaling, inducing
matrix remodeling and angiogenesis [47]. Chronic myeloge-
nous leukemia (CML) cells were also shown to release exo-
somes that affect in vitro and in vivo angiogenesis by inducing
the expression of interleukin-8 in endothelial cells. Moreover,
it was reported that HUVEC cells treated with CML exosomes
increased the expression of cell–cell adhesionmolecules such
as VCAM-1 and ICAM-1, enhancing their ability to establish
cell–cell interaction with CML cells [48].
2.3 Immunosuppressive effects of TDEs
Although the immune system can initially restrict tumor pro-
gression, its action is progressively blocked by the activation
of suppressive pathways [49] involving cell–cell contact and
the release of soluble factors [50]. Recently, mounting evi-
dence has been pointing to TDEs as major participants in the
immune evasion process (Fig. 2).
It was shown that melanoma-derived exosomes contain-
ing Fas ligand can cross-link Fas-positive T cells and trigger
their apoptotic death [51] (Fig. 2). Liu et al. have also reported
a death-independent effect of TDEs on the immune system.
They showed that the pretreatment of mice with exosomes
produced by mammary tumor cells accelerated the growth
of implanted tumor cells. This effect was related to ability
of TDEs to block IL-2-mediated activation of natural killer
(NK) cells [52]. Moreover, it was demonstrated that the TDEs
containing NKG2D ligand (such as MICA*008 or ULBP3
proteins) or membrane-bound TGF1, triggered the down-
regulation of NKG2D (an activating receptor for NK, NKT,
CD8(+), and gamma-delta(+) T cells) from the surface of NK
cells and CD8(+) T cells. This rapid and sustained exosome-
mediated decrease (Fig. 2) induced a poor functional immune
response and facilitated tumor immune evasion [53, 54].
Another immune escape mechanism mediated by TDEs
is the induction of myeloid suppressive cells proliferation
(MDSC). These are immature myeloid cells that in cancer
patients are found in large number in their lymphoid or-
gans, blood, and tumor tissues. They spontaneously secret
TGF and inhibit T-cell proliferation and cytolytic functions.
It was shown that melanoma- and colorectal carcinoma-
derived exosomes altered the monocyte differentiation into
dendritic cells, leading to the generation of myeloid suppres-
sive cells [21] (Fig. 2). Furthermore, it was demonstrated that
the MDSC-mediated promotion of tumor progression was
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dependent on both TGF- and the lipidic mediator
prostaglandinE2 (PGE2) transported by tumor exosomes [55].
2.4 TDEs and drug resistance
TDEs may indirectly contribute to tumor progression and
metastasis development by interfering with the action of ther-
apeutic agents. It was demonstrated that cisplatin-resistant
ovarian cancer cells, as well as refractory melanoma cancer
cells, actively expelled anticancer drugs by enhancing the re-
lease of exosomes [31, 56] (Fig. 2). Moreover, Safaei et al.
reported that exosomes released by cisplatin-resistant cells
were enriched in cisplatinum and expressed higher levels of
the transporters MRP2, ATP7A, and ATP7B in comparison
to sensitive cells [31]. Further studies showed that in ovarian
cancer cells, resistance to cisplatinum is also associated with
an increased secretion of annexin A3, a member of the Ca2+
and phospholipid-binding annexin family, that prevents the
uptake or accumulation of platinum in cells [57]. Electronmi-
croscopy observations have shown that annexin A3 detected
in culture medium was localized in exosomes, revealing yet
another exosome-mediated mechanism that affects a drug’s
action [58].
Recently, Battke et al. have shown that exosomes can ham-
per the action of anticancer therapies by interfering with
antibody-based drugs. The authors demonstrated that breast
cancer cell lines overexpressing HER2, release exosomes ex-
pressing a full-length HER2 molecule that is able to bind,
both in vitro and in vivo, to the HER2 antibody Trastuzumab
resulting in a reduced amount of antibodies available for the
antibody-dependent cytotoxicity (Fig. 2) [32].
2.5 TDEs-mediated horizontal transfer of RNAs
Recent findings have shown that exosomes contain both
mRNA, and miRNAs molecules that can be delivered to re-
cipient cells where they properly function [59] (Fig. 2). Valadi
et al. demonstrated that after the transfer of mouse exoso-
mal RNAs to human mast cells, new mouse proteins were
found in the target cells, indicating that transferred exoso-
mal mRNAs can be translated. Similarly, it has been demon-
strated that exosomes also transfer miRNAs into target cells,
thus regulating gene expression by their canonical binding
to the target messengers [10, 33]. The horizontal transfer of
RNAs mediated by TDEs has several consequences in the
regulation of tumor progression and metastasis [33,60,61]. A
specific role in cancer-to-endothelial cell communication was
recently reported by Umezu et al. They showed that miR-17–
92 cluster, especially miR-92a, contained in leukemia cells
(K562) exosomes can be transferred to HUVEC endothelial
cells where it significantly reduces the expression of integrin
5 (a target gene for miR-92a). Data obtained in this study
demonstrated that K562 exosomes did not affect the growth of
HUVECs, but selectively increased endothelial cell migration
and tube formation [61].
In a recent work, Fabbri et al. have showed that miR-21
and -29a, secreted by lung cancer cells via exosomes, can
also function by acting as ligands to the human Toll-like
receptor 8 (TLR8) in immune cells and by triggering a TLR-
mediated prometastatic inflammatory response. Thus, by act-
ing as paracrine agonists of TLRs, these secretedmiRNAs are
able to regulate tumor growth and spread, working as key reg-
ulators of the tumor microenvironment [60].
3 Contribution of proteomics study in
defining the protumoral role of TDEs
In the last years the increased application of proteomic tech-
nologies has significantly contributed to deeply delineate the
protein profile of exosomes from a variety of cultured cells
and body fluids (such as plasma, urine, and tumor effu-
sions) [62–66]. A part of these studies are specifically focused
on TDEs and the data are providing new insights for under-
standing their role in the regulation of tumor microenviron-
ment [62–65].
3.1 Technical features of TDE proteomics
In the field of exosome proteomics, the purification and char-
acterization of nanovesicles are the two most critical points
to control in order to avoid false-positive identifications due
to the presence of contaminating components [67]. Factors
such as biological matrices (e.g. cell culture media or bio-
logical fluids) must be carefully considered in the choice of
suitable methods for exosome purification allowing the elim-
ination of the abundant nonexosomal proteins including Igs
and albumin. The most used isolation strategies involve a
combination of different methods such as: differential cen-
trifugation, filtration, concentration, flotation density gradi-
ent, and immunocapture beads. Moreover, after a first iso-
lation step, an appropriate characterization by transmission
electron microscopy, fluorescent activated cell-sorted analy-
sis, and/or western blot is suggested to validate the relevance
of the recovered material [2, 67].
However, despite the efforts to improve the purifica-
tion of exosomes, the methods that are typically used to-
day are still not completely able to guarantee the absence
of nonexosomal contaminant proteins and for this reason
the strategies used to purify exosomes often differ between
laboratories with little consensus concerning their criteria of
purity. Nevertheless, during the last few years the advances in
proteomic technology have facilitated the collection of exten-
sive exosome protein data sets. Among the about 80 papers
on exosome proteomics (including reviews) published dur-
ing the last 80 years, less than 20 are on TDEs. Moreover,
most of them describe expression proteomic studies focused
on defining exosome proteome profiling and very often are
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Figure 3. Overview of methodological approaches in proteomic exosome research. Exosome proteins may be separated by 1- or 2DE and
proteins contained in individual bands or spots, after “in gel” trypsin digestion, are identified by MALDI-TOF/TOF or ESI-MS/MS (classical
gel-based approach). Alternatively, an exosome sample can be processed by performing a shotgun proteomic approach such as MudPIT.
This technique consists of a 2D chromatography separation of peptides generated by the enzymatic digestion of sample, followed by
MS/MS analysis on LTQ or Orbitrap. SCX: strong cation exchange.
specifically orientated toward the discovery of tumor biomark-
ers [25, 62, 63, 65, 68].
Currently, two strategies are mostly used to define an ex-
osome protein content: the first analytical approach is based
on gel electrophoresis separation followed by MS analysis;
the second one is based on the application of several shot-
gun proteomics procedures such as LC-MS/MS or multidi-
mensional protein identification technology (MudPIT) [69]
(Fig. 3).
In the former approach, proteins are first separated by
SDS-PAGE (1D or 2DE) and gel bands or spots are then
cut, trypsin-digested, and analyzed by MS. Peptide mixtures
derived from 2D gel spots that can be analyzed by PMF,
performing MALDI-TOF MS or by peptide sequencing, per-
forming an MS/MS [69,70]. For the identification of proteins
separated by 1D gel, since a single gel bandmay containmore
than one protein, the classical approach based on PMF can-
not be used. Therefore, tryptic peptides must be separated
by nanoLC systems online connected through an ESI source
with different types ofmass spectrometers [16,71] or analyzed
off-line by MALDI-TOF/TOF [65].
Alternatively, for the proteomic profiling of exosomes, gel-
freemethods such as LC-MS/MS orMudPIT have been used.
The LC-MS/MS method allows for the concentration and
isolation of hundreds of selected peptides from extremely
complex mixtures obtained through the proteolytic digestion
of proteins, before sequencing by MS [63, 72]. In MudPIT
analysis, peptides derived from digested proteins are first
separated with a strong cation exchange column followed by
a RP separation online connected to LTQ or Orbitrap mass
spectrometer, thus combining the separation steps with the
identification process [73].
3.2 Proteomics data set of TDEs
In general, the available published data on TDE proteomics
clearly shows that proteins identified in these nanovesicles
(both released by tumor cell lines and isolated from body
fluids) can be sorted into two groups: one group represents
a conserved set of proteins irrespective of exosome origin;
the second one is formed by proteins specifically related to
the producer host cell, showing that TDEs have a unique
cell-specific protein composition.
Within the group of common proteins, those most
frequently identified belong to the following classes:
membrane adhesion proteins (integrins); components of
the ESCRT machinery (alix, TSG101, vacuolar protein
sorting-associated protein 28 homolog (vps-28), vacuolar
protein sorting-associated protein 4B (vps-4B), ubiquitin-
like modifier-activating enzyme, and ubiquitin); mem-
brane transport/trafficking (annexins, Rab protein family);
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cytoskeletal components (actin, cytokeratins, ezrin, tubulin,
and myosin); lysosomal markers (lysosome membrane pro-
tein 2, cathepsin-D, CD63, LAMP-1/2); antigen presentation
proteins (HLA class I and II/peptide complexes); metabolic
enzymes (GAPDH, pyruvate, enolase alpha); HSPs (Hsc70,
Hsp70, Hsp90); kinases (LYN, MINK1, and MAP4K4);
tetraspanins (CD9, CD81, CD82, tetraspanin-8) proteases
(ADAM10, DPEP1, ST14); transporters (ATP7A, ATP7B,
MRP2, SLC1A4, SLC16A1, CLIC1); receptors (CD46, CD55,
NOTCH1) [16,26,65,70,74].Many of these proteins have been
cataloged in the ExoCartawebsite (http://www.exocarta.org/).
As more proteome studies are performed, it is becom-
ing ever more apparent that beyond the set of conserved
proteins, TDEs contain proteins that are not found in the
exosomes from both nontumor cells and/or body fluids of
healthy individuals [16,25,26,62,63,65,74,75]. All of the pro-
teomics data that have been obtained so far demonstrates that
TDEs express a discrete set of proteins specifically related to
the tumor phenotype and involved in cell proliferation, anti-
gen presentation, signal transduction, migration, invasion,
and angiogenesis, supporting the hypothesis that exosomes
may play a crucial role in modulating tumor progression and
preparing the metastatic niche.
A large amount of proteomic data regardingTDEshas been
obtained from studies on human colorectal cancer (CRC)
cell-derived exosomes. In the first global proteomic analysis
performed on exosomes released from HT29 CRC cells, a
total of 547 proteins were identified and among them 181
had never been previously described as exosome proteins.
Most of these proteins were involved in exosome biogene-
sis, but a part of them were related to processes related to
tumorigenesis [75]. In particular, this subset of 28 proteins
have a role in cancer development, including the ADAM10,
14-3-3 proteins, CD44, CD82, CD9, Alix (PDC6I), Ras-related
proteins, syntenin-1, MIF, and tetraspanin 8, which were al-
ready described in other cell-derived exosomes, as well as
the newly reported proteins in exosomes such as -catenin,
RACK1, chondroitin sulfate proteoglycan NG2, E-cadherin,
and ephrin B1. All of them contribute to the tumor pheno-
type and are differentially involved in the regulation of tumor
progression via the promotion of tumor growth, migration,
invasion, immune modulation, metastasis, and angiogene-
sis [75] (Table 1).
More recently, a comparative proteomic analysis of
LIM1215 (colorectal cancer)-derived exosomes with human
urine- and murine mast cell-derived exosomes showed
that among the 394 identified proteins, 250 were exclu-
sively present in the LIM1215 exosomes, revealing a tissue-
associated protein signature. Among them, a subset of pro-
teins known to be expressed in colorectal cancer tissues was
also found. This set included A33 antigen, cadherin-17, CEA,
epithelial cell surface antigen (EpCAM), proliferating cell nu-
clear antigen, epidermal growth factor receptor, mucin 13,
misshapen-like kinase 1, mitogen-activated protein kinase 4,
claudins (1, 3, and 7), centrosomal protein 55 kDa, ephrin-
B1 and -B2, and the enzyme phospholipid scramblase [16]
(Table 1). Interestingly, this study also revealed that the
LIM1215 exosome proteins could be categorized in some
of the seven cancer hallmark features [76, 77]. In par-
ticular, 36% belong to the category of self-sufficiency in
growth signals, 24% had a role in limitless replicative po-
tential, 17% of the proteins were upregulated in colon can-
cer metastasis, whereas 6% function in apoptosis evasion
[16].
Similar results were reported by Tauro and colleagues in a
study focused on the proteomic characterization of exosomes
derived from another colon carcinoma cell line (LIM1863).
They found that among the 171 unique proteins identified
in these exosomes, many were associated with cancer cell
proliferation, invasion, and metastasis such as c-Met protein
(hepatocyte growth factor receptor), amphiregulin (AREG),
various ephrins (EFNB1, EFNB2), and Eph receptors
(EPHA2-8, EPHB1-4), components involved in Wnt (-
Catenin and TNIK) and Ras (CRK and GRB2) signaling, and
several key components associated with colorectal cancer, in-
cluding CEACAM1 and 5, FAT1, and CDH17 [74]. It is a
well-known fact that CEACAM5 (CEA) is found to be overex-
pressed in over 90%of human gastrointestinal and pancreatic
cancers and, in particular it is associated with metastatic po-
tential in colon cancer [78, 79] (Table 1).
Additional information relative to the protein composition
of CRC exosomes was provided from the proteome profil-
ing of highly purified exosomes derived from human CRC
ascites [63]. In this study, together with proteins related to
tumor progression and already identified in previous stud-
ies [16,75], the authors reported the presence of newproteases
such as aminopeptidase N, angiotensin-converting enzyme,
which play important roles in tumor invasion, metastasis,
and angiogenesis as well as several proteins that affect ep-
ithelial cellular integrity and polarity (as galectins, Crumbs
homolog 2, adherens junction and tight-junction proteins,
and claudins) [63] (Table 1).
Other interesting data supporting the role of TDEs in tu-
mor biology was produced by proteomics studies carried out
on other types of human tumors, such as breast cancer [70],
bladder cancer [65], mesothelioma [25], melanoma [26], and
medulloblastoma [80], but also frommurine insulinoma [71].
For example, the statistically based, unbiased overrepresen-
tation analysis of human bladder cancer exosomes high-
lighted that these exosomes expressed proteins strongly re-
lated to neoplastic diseases in general and to carcinomas in
particular.
Moreover, it was demonstrated that in the biological pro-
cesses category, a large proportion of identified proteins had
functional roles in the control of the cytoskeleton, intercellu-
lar adhesion, matrix adhesion processes, and protein folding-
related processes [65]. All of these data clearly demonstrates
that TDEs are characterized by a proteome profile strongly
related to their origin and determining their functions.
Table 1 shows a summary of proteins identified in TDEs
known for their role in regulating several steps of cancer
progression.
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Table 1. Exosome proteins associated with tumor progression [16,25,26,63,65,70,71,74,75,80]
Protein name Uniprot accession Role in tumor Tumor-exosome
numbera) progression origin
14-3-3 protein beta/alpha P31946 (H) Q9CQV8 (M) Tumor growth CRC, BlC, Ins
14-3-3 protein epsilon P62258 (H) P62259 (M) Tumor growth CRC, BC, BlC, Ins
14-3-3 protein eta Q04917 (H) P68510 (M) Tumor growth CRC, Ins
14-3-3 protein gamma P61981 (H) P61982 (M) Tumor growth CRC, BC, BlC, Ins
14-3-3 protein theta P27348 (H) P68254 (M) Tumor growth CRC, BC, BlC, Ins
14-3-3 protein sigma P31947 Tumor growth, metastasis BlC
14-3-3 protein zeta/delta P63104 (H) P63101 (M) Tumor growth CRC, BC, BlC, Ins
ADAM 10 O14672 Tumor growth, migration, invasion,
angiogenesis
CRC
Adapter molecule crk P46108 Migration, invasion CRC
Alix (programmed cell death
6-interacting protein—PDC6I)
Q8WUM4 Tumor growth CRC, BC, BlC
Aminopeptidase N (CD13) P15144 Migration, angiogenesis CRC
Amphiregulin P15514 Tumor growth CRC
Angiotensin-converting enzyme P12821 Invasion, angiogenesis CRC
Annexin A1 P04083 Tumor growth, invasion CRC, BC, BlC, Mes
Annexin A2 P07355 Tumor growth, invasion CRC, BC, BlC, Mes,
Mel, MedBl
Annexin A3 P12429 Tumor growth, drug resistance CRC
Annexin A4 P09525 Tumor growth, drug resistance CRC, BC, BlC
Annexin A5 P08758 (H) P48036 (M) Tumor growth, invasion CRC, BC, BlC, Ins,
Mes, Mel
Annexin A6 P08133 Invasion CRC, BC, BlC, Mes,
Mel
Annexin A7 P20073 Tumor growth, migration, invasion BlC
Beta-2-microglobulin P61769 Immune modulation CRC, BC, BlC
Carcinoembryonic
antigen-related cell adhesion
molecule 5 precursor (CEA)
P06731 Tumor growth CRC
Basigin P35613 Migration, invasion CRC, BlC
Cadherin-1 P12830 Invasion CRC
Cadherin-17 Q12864 Invasion, metastasis CRC
Catenin beta-1 P35222 Tumor growth CRC, BlC
Catenin delta-1 O60716 Tumor growth BlC, Mel
CD151 antigen P48509 Migration, invasion CRC
CD44 P16070 Tumor growth, invasion, angiogenesis CRC, BlC
CD82 antigen P27701 Immune modulation, invasion CRC
CD9 antigen P21926 Immune modulation, migration, invasion CRC
CD97 antigen P48960 Invasion CRC
Cell division control protein 42
homolog (CDC42)
P60953 Tumor growth, invasion, metastasis CRC, BlC
Cell surface A33 antigen Q99795 Cell–cell recognition and signaling, tumor
antigen
CRC




Claudin-3 O15551 Disruption of epithelial cell polarity, invasion CRC
Claudin-7 O95471 Disruption of epithelial cell polarity, invasion CRC
Crumbs homolog 2 Q5IJ48 Disruption of epithelial cell polarity, invasion CRC
Dipeptidyl peptidase 4 P27487 Invasion CRC
DNA polymerase delta catalytic
subunit
P28340 Tumor growth, invasion CRC
Epidermal growth factor
receptor
P00533 Tumor growth, migration CRC, BlC
Epithelial cell surface antigen
(EpCAM)
P16422 Tumor growth, invasion CRC
EPH receptor B2 B1AKC9 Tumor growth, invasion CRC
EPH receptor B3 D3DNT9 Tumor growth, invasion, metastasis CRC
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Table 1. Continued
Protein name Uniprot accession Role in tumor Tumor-exosome
numbera) progression origin
Ephrin B1 P98172 Tumor growth, invasion, metastasis CRC
Ephrin B2 P52799 Tumor growth, invasion, metastasis CRC
Ezrin P15311 (H) P26040 (M) Tumor growth, migration, invasion CRC, BC, BlC, Ins,
Mel, Mes, MedBl
Fascin Q16658 Migration, invasion CRC, BC, BlC, Mes
Galectin-1 P09382 Angiogenesis, metastasis, drug resistance CRC, BlC
Galectin-3 P17931 Tumor growth CRC, BC, BlC
Galectin-3-binding protein Q08380 Migration, metastasis CRC, BC, BlC
Galectin-4 P56470 Tumor growth CRC
GST Mu 1 P10649 Tumor growth, drug resistance Ins
GST omega-1 P78417 Tumor growth, drug resistance CRC, BC
GST P P09211 (H) P19157 (M) Tumor growth, drug resistance CRC, BlC, Ins
Growth factor receptor-bound
protein 2 (Adapter protein
GRB2)
P62993 Tumor growth CRC
GTPase Kras P01116 Tumor growth CRC
Guanine nucleotide-binding
protein subunit beta-2-like 1
(RACK1)
P63244 Tumor growth, angiogenesis, CRC
Heat shock cognate 71 kDa
protein
P11142 Tumor growth CRC, BC, Mel,
MedBl
HSP beta-1 P04792 Tumor growth CRC, BC, MedBl
Hepatocyte growth factor
receptor (c-Met)







Junction plakoglobin P14923 Invasion CRC
Lin-7 homolog C Q9NUP9 Disruption of epithelial cell polarity, invasion CRC
Macrophage migration
inhibitory factor (MIF)
P14174 Tumor growth, immune modulation, invasion,
angiogenesis
CRC
Moesin P26038 Tumor growth, migration, invasion CRC, BlC, Mes, Mel
Mucin-1 P15941 Tumor growth CRC, BlC
Mucin-13 Q9H3R2 Tumor growth CRC
Mucin-16 B5ME49 Tumor growth CRC
Misshapen-like kinase 1 Q8N4C8 Tumor growth, migration CRC
Mitogen-activated protein
kinase 4
O95819 Tumor growth CRC
Olfactomedin 4 Q6UX06 Tumor growth CRC
Peroxiredoxin-1 Q06830 (H) P35700 (M) Tumor growth CRC, BC, BlC, Ins
Peroxiredoxin-2 P32119 (H) Q61171 (M) Tumor growth CRC, BC, Ins
Peroxiredoxin-3 P30048 Tumor growth CRC, BC
Peroxiredoxin-4 Q13162 (H) O08807 (M) Tumor growth BC, Ins
Peroxiredoxin-5, mitochondrial P30044 Tumor growth CRC, BlC
Peroxiredoxin-6 P30041 Invasion, metastasis CRC, BC, BlC
Phosphatidylethanolamine-
binding protein 1
P30086 Tumor growth CRC
Phospholipid scramblase 1 O15162 Tumor growth CRC
Plexin B2 O15031 Migration, invasion, angiogenesis CRC
Proliferating cell nuclear
antigen
P12004 Tumor growth CRC
Prostaglandin F2 receptor
negative regulator
Q9P2B2 Migration, invasion CRC, BlC
Protocadherin Fat 1 Q14517 Migration, invasion CRC
Radixin P35241 Tumor growth, migration, invasion CRC, BlC, Mel,
MedBl
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Table 1. Continued
Protein name Uniprot accession Role in tumor Tumor-exosome
numbera) progression origin
Ras-related protein R-Ras P10301 Invasion CRC
Ras-related protein R-Ras2 P62070 Invasion CRC
Receptor tyrosine-protein
kinase erbB-2
P04626 Tumor growth MedBl
RuvB-like 1 Q9Y265 Tumor growth CRC
Serine/threonine-protein
phosphatase 2A 65 kDa
regulatory subunit A beta
isoform
P62715 Tumor growth Ins
Serine/threonine-protein
phosphatase 2A 65 kDa
regulatory subunit A beta
isoform
P30154 (H) Q76MZ3 (M) Tumor growth CRC, Ins
Syntenin-1 O00560 Invasion CRC, mel
Tetraspanin-1 O60635 Tumor growth, migration, invasion CRC
Tetraspanin-8 P19075 Angiogenesis CRC
TNIK protein Q7Z4L4 Tumor growth CRC
Transgelin-2 P37802 (H) Q9WVA4 (M) Tumor growth CRC, BC, BlC, Ins
Trophoblast glycoprotein Q13641 Migration CRC
Tyrosine-protein kinase Lyn P07948 Tumor growth, migration CRC
Vinculin P18206 Tumor growth, invasion CRC, BC
CRC: colorectal cancer; BC: breast cancer; BlC: bladder cancer; Ins: insulinoma; Mes: mesothelioma; Mel: melanoma; MedBl: medulloblas-
toma.
a) H: human protein; M: mouse protein. Two accession numbers are reported for proteins identified in both human (CRC, BC, BlC, Mes,
Mel, MedBl) and murine cancers (Ins).
3.3 The new challenge of TDE proteomics
Most of the proteomic studies performed on TDEs up to
now have allowed for the catalogization of the proteins that
they contain. However, although TDEs’ proteins have been
also classified for their biological functions, from a Systems
Biology perspective the large-scale nature of TDE proteomics
data has been so far largely untapped.
Proteomics experimental results, beyond a rapid identi-
fication of a high number of proteins in a single analysis,
provide distinct data types that can be used to quantify pro-
teins between different proteome states, including the tem-
poral variation of the proteome, to determine the complete
primary structure of proteins including PTMs, and to deter-
mine protein interactions [81]. These aspects of expression
and functional proteomics could provide new knowledge for
understanding themechanisms of protein sorting into TDEs,
the biological meaning of some proteins in TDEs, and the in-
terrelationships between TDE proteins.
Few papers, all published during the last 3 years, have
reported data concerning quantitative and PTMs analysis of
TDE proteins, as well as data depicting protein–protein inter-
action networks in TDEs.
In a work performed on breast cancer exosomes, a quan-
titative and comparative proteomic analysis was carried out
between exosomes and whole cell lysate. This analysis re-
vealed that vesicles had a distinctive protein profile in com-
parison to the producing cell. The functional clustering of
the enriched exosomal proteins showed that most of them
belonged to functional classes of cytoskeleton, the regulation
of programmed cell death and signal proteins that, as is pub-
lished, are differentially involved in mechanisms affecting
the malignant progression of cancer [70]. Other significant
data were obtained by a quantitative proteomics study carried
out on the A431 human epidermoid carcinoma. In this work,
the authors reported that when under hypoxia, cells secreted
higher levels of proteins involved in angiogenesis, focal adhe-
sion formation, ECM-receptor interaction, and immune cell
recruitment in comparison to cells undergoing normoxic and
reoxygenation conditions. They found that more than 50% of
these secreted proteins, predominantly classified as cytoplas-
mic andmembrane proteins, were localized in exosomes [82].
Currently, newmethods of performing quantitative proteome
analyses based on differential labeling protocols or label-
free techniques as well as a vast number of software tools
for the analysis of quantitative proteomics data are almost
monthly described in the literature [69, 83–85]. During the
next few years, the application of these accurate quantitative
techniques could represent one of most challenging issues in
the field of TDE proteomics.
Although it is well known that the identification of PTMs
is very often essential for understanding the real function
of proteins and their localization within cells or cell or-
ganelles, only one paper in the published literature reports
data concerning PTMs of exosomal proteins. In this work,
Lee and co-workers analyzed exosomes derived from murine
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insulinoma cells and showed that some proteins (such as
ubiquitin and HSP90) were present in secreted vesicles as
multiple populations, distinct from those observed in cell
lysate. By analyzingdata obtained combining techniques such
as 1D gel separation, western blot, and nanoLC-ESI-q-TOF
MS/MS, the authors highlighted that these multiple forms of
a same protein were due to several PMTs, including ubiqui-
tination and phosphorylations. On the basis of these obser-
vations, they propose that some uniquely modified proteins
could be located in exosomes. However, the relationship be-
tween PTMs detected in exosomes and their biogenesis or
their functions was not further investigated and no more
data are currently available.
Doubtless, different independent difficulties (such as low
abundance, lability of the modifications) have made it chal-
lenging to perform a PTM global analysis so far. However,
technological advances inMS-based proteomics have allowed
some critical points to be overcome andMS-based PTM anal-
ysis is now quite successful. Good results have been produced
not only for phosphorylation (themore studiedPTM), but also
for lysine acetylation or methylation,N-glycosylation, ubiqui-
tination, sumoylation, and others that have also been inves-
tigated in a quantitative manner [81] and references therein].
The possibility to characterize the PTMs in TDEs proteins as
well as their functional effects, may represent an outstand-
ing development of TDEs proteomic studies, furthering our
understanding of TDE roles in tumor microenvironment.
Finally, today the characterization of protein networks is
a highly valued goal of the postgenomic studies. However,
this aspect remains almost completely unexplored in the
field of exosome proteomics. The only data available in lit-
erature comes from two recent studies in which exosomes
derived from human medulloblastoma and colorectal carci-
noma cells were analyzed. Proteomic data obtained in these
studies allowed the construction and analysis of protein–
protein interaction networks for TDEs for the first time,
revealing that exosomal proteins are closely interconnected
via physical interactions and cluster into functional modules
involved in the biogenesis of exosomes and in several pro-
cesses regulating tumor progression (as cell proliferation,
cell migration, and immune suppression) [80, 86]. Interest-
ingly, what has clearly emerged from the work on CRC-
derived exosomes is that these TDEs have several hub pro-
teins, with many other vesicular proteins that have few inter-
acting partners, and well-connected clusters similar to those
identified in other subcellular networks. However, there is a
significant amount of evidence that indicates that groups of
proteins with roles in specific biological processes andmolec-
ular functions are highly enriched or depleted in TDEs, sug-
gesting that TDEs are extracellular organelles distinct from
other intracellular organelles and compartments [86]. Fur-
ther Systems Biology approaches could provide a new in-
tegrated view of TDEs, and the resulting interactome data,
analyzed extensively through bioinformatic methods, would
offer new tools for defining the organization and function of
exosomes.
In conclusion, the involvement of TDEs in promoting tu-
mor progression is supported by all of the proteomic data
obtained from several types of tumors. However, up until
now the exosome proteomic study has been often utilized to
catalog TDEs’ proteins in order to find disease biomarkers
rather than to predict the functional activities of the vesicles.
Thus, new efforts must currently focus on the development
of new perspectives to perform adequate quantitative, PTMs,
and protein interaction analyses with the aim of creating pre-
dictive models of TDEs in the field of Systems Biology.
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